)
)
)
RND Pharmaceuticals Inc.
RND is a New York-based company with a two-fold business model:
- The development of a novel and proprietary test (RND-101) for the prediction of resistance to Immune Checkpoint Inhibitors (ICI). A strong correlation between our proprietary panel and ICI outcomes has been demonstrated. Preliminary data was presented at SITC, 2025 (J Immunother Cancer 2025; 13 (Suppl 2): A1-A1534; Abstract 52). We are seeking collaborations with Diagnostics companies.
- We have identified and validated novel targets for Therapeutics development to overcome resistance to ICI. We are seeking collaborations with Pharma and Biotech companies.
The predictive test (RND-101) will use baseline tumor biopsy tissue to enable patient selection for ICI therapy.
In addition, this predictive test could be used to enrich for potential responders, and hence reduce trial sample size, cost and risk with Clinical Trials using ICI.
We welcome the opportunity to discuss a potential collaboration with you.
Address
New YorkNew York
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)